This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n13http://dx.doi.org/10.1200/
n11https://w3id.org/oc/corpus/br/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q29619653
rdf:type
wikibase:Item
schema:description
مقالة علمية (نشرت في نوفمبر 2010) wetenschappelijk artikel (gepubliceerd op 2010/11/01) scientific article (publication date: November 2010) im November 2010 veröffentlichter wissenschaftlicher Artikel 2010 թվականի նոյեմբերին հրատարակված գիտական հոդված artículu científicu espublizáu en 2010 наукова стаття, опублікована в листопаді 2010 2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
p:P577
wds:Q29619653-CF812541-F463-42A4-9FF2-35A2BBF02453
wdt:P577
2010-10-04T00:00:00Z
p:P407
wds:Q29619653-0A3C3C0E-4F18-4521-AEDD-63069189363F
wdt:P407
wd:Q1860
p:P2860
wds:Q29619653-D9D40D89-7B9C-4716-9AD0-A5C342FD9651
wdt:P2860
wd:Q29547625
p:P2093
wds:Q29619653-1CACE274-810A-483D-9500-ED9DA606164E wds:Q29619653-3CB881B6-5163-419B-8391-3AE13E2599D8 wds:Q29619653-953DC40D-8BCE-4985-BEC6-AA4CB82D887A wds:Q29619653-89F5D0D7-57B1-4BEC-AC61-F59D9FC8009A wds:Q29619653-94933F16-5D3D-4A94-876F-AE162818F3DB wds:Q29619653-A9CE2475-78C1-4E9E-A447-12425694F52A wds:Q29619653-CF04454C-EE2B-4781-9BCB-4E9D2F6643B2 wds:Q29619653-AD2621CD-D37D-4740-B41E-3C9D362E06F7 wds:Q29619653-B3C1435F-925E-4EB8-807A-355942106498 wds:Q29619653-EE6C554D-53F4-44EB-A95F-81A30D9A25BE
p:P3181
wds:Q29619653-80A82562-7F1A-4D81-9123-103E7A67C96A
wdtn:P3181
n11:191238
wdt:P2093
Kelly S Oliner Fernando Rivera Michael Wolf Yves Humblet James Cassidy Ronald Burkes Jennifer Gansert Jean-Luc Canon Ilona Kocákova Paul Ruff
wdt:P3181
191238
rdfs:label
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
skos:prefLabel
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
schema:name
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
p:P50
wds:Q29619653-4ED49EDE-9C3C-4A84-85C0-063CF92C410A wds:Q29619653-5258F5BE-BB4D-4B4C-917D-551F4C630C6C wds:Q29619653-86BAFF7B-4997-4534-9E62-A69EE62729A1 wds:Q29619653-25556B4B-0DBC-408E-9266-6431EF3411DA wds:Q29619653-3387FBDC-FCAF-492C-9412-DAB7812E0C3B wds:Q29619653-404CAC33-69C5-4C9F-BE84-6701D4A44009 wds:Q29619653-A85ED52A-BC96-43AA-BBA7-EE09F4208268 wds:Q29619653-F95563D5-CB4D-4E2D-85F8-6108471A005C wds:Q29619653-079D4C7B-D252-4130-8CC4-8ECC7A61A723 wds:Q29619653-11ACBCCF-A8BE-490C-AF3F-52553B64E93A
wdt:P50
wd:Q57963303 wd:Q125317185 wd:Q19690551 wd:Q37387600 wd:Q56754501 wd:Q125317317 wd:Q46772644 wd:Q38803238 wd:Q83677686 wd:Q125317460
p:P1476
wds:Q29619653-A922B728-9D1C-49CB-A6CA-0A9A8ABE9EEF
wdt:P1476
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
p:P304
wds:Q29619653-0C2DC3F8-B073-4375-A36D-153C6BC59431
wdt:P304
4697-4705
p:P31
wds:Q29619653-47C93D79-0DAF-4F0A-9B18-3AF4B89F2B4C
wdt:P31
wd:Q13442814
p:P921
wds:Q29619653-77ADC889-8708-42A7-875C-B41D4570D2FB wds:Q29619653-1E4CE1F2-C08D-450D-B972-D667B75B9E2D wds:Q29619653-ED2C24F2-5745-4148-B16F-7D759E4518A3 wds:Q29619653-C478B84B-96B4-4E2A-8141-90F6AB358EAF wds:Q29619653-D17265C9-86BC-4416-A35B-C12FF3587639 wds:Q29619653-D24C0C03-CB53-44F2-B682-14FA2A546F6A wds:Q29619653-4DA66185-5CFA-46BE-B7BB-A655FB611F2A
wdt:P921
wd:Q181600 wd:Q422327 wd:Q42824827 wd:Q238512 wd:Q188874 wd:Q25493920 wd:Q108566365
p:P698
wds:Q29619653-A0014DFE-5E68-44A6-BC72-5A9C3ACC4A6A
wdtn:P698
n10:20921465
wdt:P698
20921465
p:P1433
wds:Q29619653-A80DFA81-81A8-4E1D-BAF4-A6EC1888F900
wdt:P1433
wd:Q400292
p:P433
wds:Q29619653-5CA486B0-D8EF-4288-9EF6-D3FC7FCB92F3
p:P478
wds:Q29619653-6D1FF16F-4FD7-4153-B571-B3CCE9CF5676
wdt:P433
31
wdt:P478
28
p:P356
wds:Q29619653-4D0C0399-B09E-406F-96CB-E7EDF6734EF1
wdtn:P356
n13:JCO.2009.27.4860
wdt:P356
10.1200/JCO.2009.27.4860